All News

In this clip, Debra Goff, PharmD, FCCP, infectious disease clinical pharmacist and Associate Professor at The Ohio State University, tells Pharmacy Times about One Health, a movement dedicated to bringing together different fields that handle antibiotics to prevent the misuse of these bacteria-killing drugs.

The FDA accepted a supplemental New Drug Application for olaparib’s (Lynparza) new indication for first-line maintenance treatment of advanced ovarian cancer.

New research underscores the value of review by an ID physician, nurse, or pharmacist before starting OPAT.

The recently launched tool allows patients to efficiently manage their program in real-time.

The FDA accepted a supplemental New Drug Application for olaparib’s (Lynparza) new indication for first-line maintenance treatment of advanced ovarian cancer.

Top news of the day from across the health care landscape

Top news of the day from across the health care landscape

Sofosbuvir, velpatasvir, and voxilaprevir successful in patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence to direct-acting antiviral drug regimens.

Former New York Giants running back Tiki Barber discusses his mother's fight against breast cancer and his advocacy for cancer awareness.

A new report published in the CDC Morbidity and Mortality Weekly Report (MMWR) has linked cases of acute hepatitis A virus (HAV) infections from certain states to person-to-person transmission from drug use or homelessness.

The epidemiology of hepatitis A has shifted from point-source outbreaks to outbreaks caused by person-to-person transmission.

Top news of the day from across the health care landscape

Top news of the day from across the health care landscape

People who inject drugs may still able to achieve a cure of hepatitis C virus infection with treatment with direct-acting antivirals.

Testing DNA through plasma or urine rather than tissue offers health care providers an alternative method to evaluate potential treatment resistance.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

The FDA approved Merck’s pembrolizumab (Keytruda) for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

The FDA approved Merck’s pembrolizumab (Keytruda) for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.

Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.

If approved, avatrombopag (Doptelet) would also be indicated for the treatment of chronic immune thrombocytopenia in patients who have had insufficient response to a previous therapy.

Although malignant melanoma incidence has stabilized or declined in women, melanoma-associated mortality rates have risen among men throughout the world.

Top news of the day from across the health care landscape

Top news of the day from across the health care landscape

Top news of the week from Specialty Pharmacy Times.

The action will increase access to diagnostic tools for healthcare providers who may not have otherwise been equipped to perform tests.

New data presented at the 2018 ACR/ARHP Annual Meeting shows that the treatment regimens for many patients are not being changed to reach a “treat-to-target” goal for low disease activity.

An up-to-date analysis of melanoma mortality rates show that deaths among men are rising, but stabilizing or decreasing in women.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.